Viking Therapeutics Inc
NASDAQ:VKTX

  • LAST PRICE
    70.4700
  • TODAY'S CHANGE (%)
    2.3100 (3.3891%)
  • Bid / Lots
    70.5600/ 5
  • Ask / Lots
    70.8000/ 6
  • Open / Previous Close
    69.5000 / 68.1600
  • Day Range
    68.5100
    72.3600
  • 52 Week Range
    8.2800
    99.4100
  • Volume
    7,998,530

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
VKTX
Viking Therapeutics Inc
7.6B
-75.1x
---
RVMD
Revolution Medicines Inc
7.7B
-12.5x
---
NUVL
Nuvalent Inc
6.7B
-38.8x
---
CYTK
Cytokinetics Inc
6.5B
-10.0x
---
MDGL
Madrigal Pharmaceuticals Inc
5.3B
-9.2x
---
RNA
Avidity Biosciences Inc
5.3B
-15.1x
---
As of 2024-09-22

Company Information

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Contact Information

Headquarters
9920 Pacific Heights Blvd, Suite 350SAN DIEGO, CA, United States 92121
Phone
858-704-4660
Fax
302-636-5454

Executives

Independent Chairman of the Board
Lawson Macartney
President, Chief Executive Officer, Director
Brian Lian
Chief Financial Officer
Greg Zante
Chief Operating Officer
Marianne Mancini
Independent Director
Matthew Foehr

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$7.8B
Revenue (TTM)
$0.00
Shares Outstanding
110.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.00
EPS
$-0.94
Book Value
$3.48
P/E Ratio
-75.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.